New hope for kids with Hard-to-Treat tumors: radioactive therapy trial opens
NCT ID NCT06441331
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times
Summary
This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with tumors that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario Vall d'Hebron - Oncología Médica
RECRUITINGBarcelona, 08035, Spain
Contact Email: •••••@•••••
-
The Children's Hospital of Philadelphia (CHOP)
RECRUITINGPhiladelphia, Pennsylvania, 19104-4319, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.